Search or
𝛼SK
𝛼SKbullish
Sam Chun Dang Pharm (000250 KS): Oral Semaglutide Trial Begins; Global Expansion of Eylea Biosimilar
5.2k Views14 Mar 2025 08:30
SUMMARY
- Sam Chun Dang Pharm (000250 KS) has commenced bioequivalence study of oral semaglutide. Difference in technology should allow the drug to enter the market as early as 2026.
- Last December, the company has partnered with Fresenius Kabi for the global commercialization of its Eylea biosimilar in the U.S. and several countries in Latin America.
- Sam Chun Dang Pharma shares rallied 113% since its early December lows. With continued progress of high-value generics, we remain upbeat on the name.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
x